Inactive Instrument

Press Releases Lonza Group AG Swiss Exchange

Equities

CH0013841017

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

05-14	Swiss Market Index Edges Up Ahead of Inflation Report	MT
05-14	Global markets live: Apple, Sony, Vodafone, Booking, Walmart...

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lonza : Q1 2024 Qualitative Update	05-14	PU
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024	05-14	EQ
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved	05-08	EQ
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon	04-17	EQ
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports	04-03	EQ
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer	04-02	EQ
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche	03-20	EQ
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza	01-26	EQ
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin	01-26	EQ
Lonza : Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency	11-14	PU
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds	11-06	EQ
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects	23-10-17	EQ
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer	23-10-13	EQ
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023	23-09-21	EQ
Board Announcement	23-09-18	EQ
Lonza : Half-Year 2023 Results Report	23-07-21	PU
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin	23-07-21	EQ
Lonza : Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture	23-07-17	PU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies	23-06-27	AQ
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering	23-06-01	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

LONZA GROUP : Some mixed real-world effects

February 06, 2024 at 10:44 am